Skip to main content
Premium Trial:

Request an Annual Quote

Phase II Promises Don't Always Materialize in Phase III

In the Pipeline's Derek Lowe reminds his readers that interesting Phase II results don't always translate into successful Phase III tests. He points to Antisoma's AS404 and GenVec's TNFerade as examples. Both companies announced that their Phase III trials were being halted after it became clear that neither was going to meet its endpoints. Antisoma, and its partner Novartis, had been developing AS404 as an addition to oncology treatments, Lowe says, but the trial was halted after an interim analysis showed "basically no hope of it showing benefit if things continued." And the trial for GenVec's TNFerade – a gene therapy approach to induce TNF-alpha expression in tumors that was being studied for use as a pancreatic cancer treatment – was also halted.

So is Phase II testing meaningless? Not at all, Lowe says. Phase II trials are smaller and their patient populations more carefully selected – they're designed to show some reason to proceed and often do, he adds. "If your drug candidate makes it through Phase II, that may say more about how you designed the trial than it says about the compound," Lowe writes.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.